deltatrials
Completed PHASE2 INTERVENTIONAL 4-arm NCT02312245

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Avatar-Directed Chemotherapy in Platinum-Resistant Ovarian, Primary Peritoneal and Fallopian Tube Cancers

Sponsor: Mayo Clinic

Conditions Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma
Interventions Bevacizumab Gemcitabine Hydrochloride Paclitaxel Pegylated Liposomal Doxorubicin Hydrochloride Topotecan Hydrochloride
Updated 15 times since 2017 Last updated: Nov 12, 2024 Started: Jul 21, 2015 Primary completion: Apr 24, 2023 Completion: Apr 24, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Recurrent Fallopian Tube Carcinoma and Recurrent Ovarian Carcinoma, this trial is completed. The trial is conducted by Mayo Clinic and has accumulated 15 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Aug 2018 · 2 months · monthly snapshot~Aug 2018 – ~Aug 2019 · 12 months · monthly snapshot~Aug 2019 – ~Aug 2020 · 12 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~May 2022 · 12 months · monthly snapshot~May 2022 – ~Jul 2022 · 2 months · monthly snapshot~Jul 2022 – ~Jun 2023 · 11 months · monthly snapshot~Jun 2023 – ~Jul 2024 · 13 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jan 2025 · 4 months · monthly snapshot~Jan 2025 – present · 17 months · monthly snapshot

Change History

15 versions recorded

  1. Jan 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Jan 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jun 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  5. Jul 2022 — Jun 2023 [monthly]

    Recruiting PHASE2

▶ Show 10 earlier versions

  1. May 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  2. May 2021 — May 2022 [monthly]

    Recruiting PHASE2

  3. Jan 2021 — May 2021 [monthly]

    Recruiting PHASE2

  4. Aug 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  5. Aug 2019 — Aug 2020 [monthly]

    Recruiting PHASE2

  6. Aug 2018 — Aug 2019 [monthly]

    Recruiting PHASE2

  7. Jun 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  8. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

  9. Feb 2017 — Jul 2017 [monthly]

    Recruiting PHASE2

  10. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Mayo Clinic
  • National Cancer Institute (NCI)
Data source: Mayo Clinic

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations